Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | PI4KA | P42356 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.53 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.53 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7403740 | 0.75 | XDH (0.35) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL29351045 | 0.70 | XDH (1.00) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL11363 | 0.70 | XDH (1.00) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL13829440 | 0.69 | RET (0.52) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL6527123 | 0.68 | ALDH1A1 (0.36) | XDHRETPI4KALRRK2PI4K2B | |
| Hydrochloric Acid SCHEMBL1741653 | 0.68 | XDH (0.96) | XDHRETPI4KALRRK2PI4K2B | |
| Hydrochloric Acid SCHEMBL30403903 | 0.68 | XDH (0.96) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL1014920 | 0.68 | XDH (0.55) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL29487078 | 0.68 | XDH (0.55) | XDHRETPI4KALRRK2PI4K2B | |
| Benzene SCHEMBL25427466 | 0.65 | RET (0.52) | XDHRETPI4KALRRK2PI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8071608-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071585-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010116176-A1 | PYRAZOLO [4, 5-E] PYRIMIDINE DERIVATIVE AND ITS USE TO TREAT DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010116177-A1 | A PYRAZOLO [4,5-E] PYRIMIDINE DERIVATIVE AND ITS USE TO TREAT DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261733-A1 | THERAPEUTIC AGENTS 927 | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261704-A1 | THERAPEUTIC AGENTS 928 | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
| US-7186725-B2 | Anti-inflammatory compositions and methods | GENZYME CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20040180871-A1 | Anti-inflammatory compositions and methods | GENZYME CORPORATION | 2004-09-16 | — | — | US | disclosed |
| WO-2004063181-A1 | UREA DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | GENZYME CORPORATION (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261704-A1 | THERAPEUTIC AGENTS 928 | GCK, GCKR, GALK1 | XDH 2399/4885RET 2702/4885PI4KA 208/4885 |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | XDH 788/4885RET 3389/4885PI4KA 486/4885 |
| US-20040180871-A1 | Anti-inflammatory compositions and methods | CD4, LCP2, IL6 | XDH 889/4885RET 3911/4885PI4KA 3718/4885 |
| US-20100261733-A1 | THERAPEUTIC AGENTS 927 | GCK, GCKR, GALK1 | XDH 3137/4885RET 1961/4885PI4KA 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.